孙福礼^1,,
吕丽¹,
吕秀鹏²,
汪文博^1,,
1. 大连医科大学附属第二医院 病理科，辽宁 大连 116027
2. 大连医科大学附属第一医院 肿瘤放疗科，辽宁 大连 116011

基金项目: 辽宁省自然基金指导项目（2019-ZD-0633）


详细信息 作者简介: 孙福礼（1995-），女，硕士研究生。E-mail：1394952509@qq.com




通讯作者: 汪文博，主管技师。E-mail：boleyn1986@qq.com 中图分类号: R365


摘要:目的分析ERα36表达与乳腺癌患者临床病理特征之间的关系，以及ERα36和HER2不同表达水平患者的预后情况。方法 收集2008年1月至2018年12月大连医科大学附属第二医院经病理确诊的61例乳腺癌患者的癌及癌旁组织标本及临床病例资料，采用qPCR检测标本中ERα36 mRNA的表达量，采用免疫组化及FISH方法检测标本HER2表达。分析ERα36表达量与临床病理特征之间的关系、ERα36和HER2不同表达水平与患者预后的关系。结果 乳腺癌组织与癌旁组织比较，ERα36 mRNA的表达量增高（P＜0.05）。根据ERα36 mRNA表达量值，将61例乳腺癌患者分为ERα36高表达组42例（表达量值≥1）和ERα36低表达组19例（表达量值＜1）。ERα36高表达组中已绝经者占83.33%，高于ERα36低表达组的16.67%；ERα36高表达组淋巴结转移（N1～3）者占81.82%，高于ERα36低表达组的18.18%，差异均有统计学意义（P＜0.05）。而年龄、生育史、家族史、临床分期、组织学分级、乳头大导管浸润、T分期、M分期在ERα36高表达组与低表达组之间差异无统计学意义。ERα36高表达组无进展生存期（progression free survival，PFS）较ERα36低表达组短，同时ERa36高表达HER2阳性组PFS较 ERa36低表达HER2阴性组短，P均＜0.05。各组间总生存期（overall survival，OS）未见明显差异。结论 ERα36 mRNA在乳腺癌组织内表达增加，可能促进乳腺癌淋巴结转移；ERα36高表达HER2阳性患者预后不良。
关键词: ERα36/
HER2/
乳腺癌/
预后


Abstract:ObjectiveTo analyze the relationship between expression of ERα36 and clinicopathological features of breast cancer patients, and the prognosis of patients with different levels of ERα36 and HER2 expression.MethodsThe specimens and clinical data of 61 patients with breast cancer diagnosed by pathology in the Second Affiliated Hospital of Dalian Medical University from January 2008 to December 2018 were collected. The expression of ERα36 mRNA in the samples was determined by qPCR, and the expression of HER2 was detected by immunohistochemical and FISH methods. We analyzed the relationship between the expression of ERα36 and clinicopathological features, and the relationship between the expression of ERα36 and HER2 and the prognosis of patients.ResultsThe expression of ERα36 mRNA in breast cancer tissues was higher than that in paracancerous tissues (P＜0.05). According to the expression of ERα36 mRNA, 61 breast cancer patients were divided into high expression group of ERα36 (42 cases, expressive quantity value ≥ 1) and low expression group of ERα36 (19 cases, expressive quantity value ＜1). The percentage of menopause in ERα36 high expression group was 83.33%, higher than 16.67% in ERα36 low expression group. Lymphnode metastasis was detected in 81.82% patients of ERα36 high expression group and 18.18% of ERα36 low expression group. The difference was statistically significant (P＜0.05). There were no significant difference in age, reproductive history, family history, clinical stage, histological grade, nipple duct infiltration, T stage and M stage between ERα36 high expression group and low expression group. The progression free survival (PFS) of ERα36 high expression group was shorter than that of ERα36 low expression group, and the PFS of ERa36 high expression HER2 positive group was shorter than that of ERa36 low expression HER2 negative group (P＜0.05). There was no significant difference in overall survival (OS) among groups.ConclusionThe increased expression of ERα36 mRNA in breast cancer may promote lymph node metastasis, and ERα36 high expression HER2 positive patients have a poor prognosis.
Keywords:ERα36/
HER2/
breast cancer/
prognosis

PDF全文下载地址:

https://journal.dmu.edu.cn/data/article/export-pdf?id=640aa3a3fa89b2af1f87250f